![Drew Moghanaki: A common-sense interpretation of clinical trial data](https://oncodaily.com/pub/uploads/2024/09/bdf604be40434f58ad5aca6db64c3d69.jpg)
Drew Moghanaki/uclahealth.org
Feb 10, 2025, 16:08
Drew Moghanaki: A common-sense interpretation of clinical trial data
Drew Moghanaki, Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA, shared a post on X about a paper by Nasser Altorki and Benjamin Lee published in Journal of Thoracic Oncology:
“Once again, Nasser Altorki provides a common-sense interpretation of clinical trial data that can be easily misinterpreted by those who are used to analyzing data with conventional wisdom.
Friendly reminder of reasons why conventional wisdom can be misleading.
Here is the article that’s referenced.”
“Reducing Local Recurrence After Sublobar Resection: Not As Easy As It Seems”
Authors: Nasser Altorki, Benjamin Lee.
More posts featuring Drew Moghanaki.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 10, 2025, 16:08
Feb 10, 2025, 15:56
Feb 10, 2025, 15:38
Feb 10, 2025, 15:34
Feb 10, 2025, 15:21
Feb 10, 2025, 15:11
Feb 10, 2025, 14:47
Feb 10, 2025, 14:12